DDMAC issues untitled letter concerning Ista journal ad

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) issued an untitled letter to Ista Pharmaceuticals concerning a journal advertisement for Vitrase (hyaluonidase injection), indicated for the treatment of vitreous hemorrhage and diabetic retinopathy.
In the letter, DDMAC said the journal ad is false or misleading because it fails to reveal material
facts, thus minimizing the risks associated with treatment with Vitrase. "DDMAC requests that Ista immediately cease the dissemination of violative promotional materials for Vitrase," the letter stated.
A spokesperson for Ista was not immediately available for comment.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.